165 related articles for article (PubMed ID: 22368893)
1. Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: experience at Sindh Institute of Urology & Transplantation (SIUT).
Tunio MA; Hashmi A; Rafi M; Qayyum A; Masood R
J Pak Med Assoc; 2011 Jan; 61(1):6-10. PubMed ID: 22368893
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
6. An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
Feng YH; Shen KH; Huang KH; Tzeng WS; Li CF; Lin KL
Clin Genitourin Cancer; 2016 Feb; 14(1):e67-74. PubMed ID: 26428609
[TBL] [Abstract][Full Text] [Related]
7. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T
Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
Choudhury A; Swindell R; Logue JP; Elliott PA; Livsey JE; Wise M; Symonds P; Wylie JP; Ramani V; Sangar V; Lyons J; Bottomley I; McCaul D; Clarke NW; Kiltie AE; Cowan RA
J Clin Oncol; 2011 Feb; 29(6):733-8. PubMed ID: 21205754
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder.
Sung HH; Kim H; Kim R; Kim CK; Kwon GY; Park W; Song W; Jeong BC; Park SH
Investig Clin Urol; 2022 Mar; 63(2):168-174. PubMed ID: 35244990
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
[TBL] [Abstract][Full Text] [Related]
11. Novel bladder preservation therapy for locally invasive bladder cancer: combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
Azuma H; Inamoto T; Ibuki N; Ubai T; Kotake Y; Takahara K; Kiyama S; Nomi H; Uehara H; Komura K; Yamamoto K; Narumi Y; Katsuoka Y
Int J Oncol; 2010 Oct; 37(4):773-85. PubMed ID: 20811698
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy.
Wu CE; Lin YC; Hong JH; Chuang CK; Pang ST; Liaw CC
Anticancer Res; 2013 Jun; 33(6):2605-10. PubMed ID: 23749915
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.
Khaled HM; Shafik HE; Zabhloul MS; Ghoneim M; Saber RA; Manie M; Enein HA; Megeed HA; Mansur O; Sherbini ME; Mahran TZ; Kalawee ME; Badran A; Ramadan SM
Clin Genitourin Cancer; 2014 Oct; 12(5):e233-40. PubMed ID: 24889794
[TBL] [Abstract][Full Text] [Related]
15. Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy.
Chen J; Miranda G; Cai J; Daneshmand S; Djaladat H
Scand J Urol; 2019; 53(2-3):123-128. PubMed ID: 31081431
[No Abstract] [Full Text] [Related]
16. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
[TBL] [Abstract][Full Text] [Related]
17. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
Gamal El-Deen HS
J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
[TBL] [Abstract][Full Text] [Related]
18. A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement.
Chiang Y; Cheng JC; Huang CY; Tsai YC; Lin CC; Hsu CH; Cheng AL; Pu YS
J Formos Med Assoc; 2017 Sep; 116(9):689-696. PubMed ID: 28034491
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer.
Thompson C; Joseph N; Sanderson B; Logue J; Wylie J; Elliott T; Lyons J; Anandadas C; Choudhury A
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):732-739. PubMed ID: 28244408
[TBL] [Abstract][Full Text] [Related]
20. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.
Huo J; Ray-Zack MD; Shan Y; Chamie K; Boorjian SA; Kerr P; Jana B; Freedland SJ; Kamat AM; Mehta HB; Williams SB
Eur Urol Oncol; 2019 Sep; 2(5):497-504. PubMed ID: 31411998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
